» Articles » PMID: 3117132

Flow Cytometric Analysis of Human Bone Marrow. II. Normal B Lymphocyte Development

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1987 Nov 1
PMID 3117132
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

A panel of B lymphoid-reactive monoclonal antibodies was used to analyze the phenotypic changes that accompany B lymphocyte development in normal human bone marrow. The B lymphoid cells were identified using light scattering and the expression of CD19 on a flow cytometer. Quantitative three-color immunofluorescence was then used to correlate other cell surface antigens on these cells identified as B lymphoid in normal marrow. CD10 and CD20 identified almost exclusive populations and provided a convenient means of discriminating between the less and more mature B lineage cells. The CD10+ cells could be further subdivided using CD34. The population of CD19+, CD10+, CD34+ cells comprised only 0.6% of marrow cells, but these contained the majority of terminal deoxynucleotidyl transferase (TdT+) cells. In the assessment of class II antigens, HLA-DR was expressed on all B lineage cells whereas HLA-DP preceded HLA-DQ in appearance during the developmental process. Among the later antigens expressed on B lineage cells, cell surface IgM, CD20, and HLA-DQ were expressed at essentially the same time. Cell surface CD10 was lost at the time when CD21 and CD22 were acquired on the cell surface. These data illustrate that multiparameter flow cytometry can be used to define a continuous progression of stages of B lymphocyte development based on cell surface antigen expression even though these cells represent a minor fraction of normal marrow cells.

Citing Articles

What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study.

DArena G, Vitale C, Pietrantuono G, Villani O, Mansueto G, DAuria F Cancers (Basel). 2024; 16(2).

PMID: 38275909 PMC: 10814247. DOI: 10.3390/cancers16020469.


Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab.

Lopedote P, Shadman M Cancer Manag Res. 2023; 15:257-264.

PMID: 36941881 PMC: 10024536. DOI: 10.2147/CMAR.S381493.


Single-cell analysis reveals dynamics of human B cell differentiation and identifies novel B and antibody-secreting cell intermediates.

Verstegen N, Pollastro S, Unger P, Marsman C, Elias G, Jorritsma T Elife. 2023; 12.

PMID: 36861964 PMC: 10005767. DOI: 10.7554/eLife.83578.


Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD.

Shi M, Chu F, Jin T, Zhu J CNS Neurosci Ther. 2022; 28(7):981-991.

PMID: 35426485 PMC: 9160456. DOI: 10.1111/cns.13836.


The Involvement of Macrophage Colony Stimulating Factor on Protein Hydrolysate Injection Mediated Hematopoietic Function Improvement.

Wang S, Zhang Y, Meng W, Dong Y, Zhang S, Teng L Cells. 2021; 10(10).

PMID: 34685756 PMC: 8534652. DOI: 10.3390/cells10102776.